• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice. Rheumatology >Are cannabinoids a new treatment option for pain in patients with fibromyalgia?
【24h】

Are cannabinoids a new treatment option for pain in patients with fibromyalgia?

机译：大麻素是纤维肌痛患者疼痛的新治疗选择吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Preliminary studies suggest that the synthetic cannabinoid nabilone might be an effective therapy in patients with fibromyalgia. Skrabek et al. performed a double-blind, randomized, placebo-controlled clinical trial to analyze the effects of nabilone on pain and quality of life in patients with fibromyalgia. After 4 weeks of treatment (0.5 mg once daily in week 1, 0.5 mg twice daily in week 2, 0.5 mg in the morning and 1 mg in the evening in week 3, and 1 mg twice daily in week 4), patients who received nabilone (n = 15) experienced significant improvements in clinical pain, measured on a visual analog scale (P <0.02), Fibromyalgia Impact Questionnaire score (P <0.02) and the 10-point anxiety scale of the Fibromyalgia Impact Questionnaire (P <0.02). After a 4-week wash-out period at the end of the trial, all benefits were lost in the nabilone cohort, which returned to their baseline levels of pain and quality of life. Patients who received placebo (n = 18) experienced no change throughout the study. Although nabilone was not associated with serious adverse effects, some patients did experience drowsiness, dry mouth, vertigo and ataxia as a result of treatment.
机译：初步研究表明，合成的大麻素萘比隆可能是治疗纤维肌痛的有效疗法。 Skrabek等。进行了一项双盲，随机，安慰剂对照的临床试验，以分析萘比隆对纤维肌痛患者的疼痛和生活质量的影响。经过4周的治疗（第1周每天0.5 mg，第2周每天0.5 mg，第2周每天0.5 mg，第3周晚上1 mg，第4周每天1 mg，第2周每天两次），接受萘比隆（n = 15）在视觉上的模拟疼痛量表（P <0.02），纤维肌痛影响问卷调查得分（P <0.02）和纤维肌痛影响问卷的10分焦虑量表（P <0.02 ）。在试验结束后的4周冲洗期后，萘比隆研究组失去了所有益处，这又恢复到基线水平的疼痛和生活质量。在整个研究过程中，接受安慰剂的患者（n = 18）没有变化。尽管萘比隆与严重的不良反应无关，但由于治疗，有些患者确实出现了嗜睡，口干，眩晕和共济失调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号